This Biotech Name Is Flying Under the Radar! ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
_You are receiving this email because you are subscribed to MORNING
WATCHLIST FROM BEHIND THE MARKETS. If you no longer wish to receive
these partner emails, please unsubscribe
[[link removed]]
here. This message is from Equiscreen._
-------------------------
AVAI IS MOVING FAST IN THE LONGEVITY RACE—AND THIS KLOTHO
BREAKTHROUGH COULD BE THE EARLY SIGNAL INVESTORS DON’T WANT TO MISS
[[link removed]]
A [[link removed]]VAÍ BIO, INC. (OTCQB: AVAI)
[[link removed]] just hit a key inflection
point—launching GMP production of its Master Cell Bank for its
α-Klotho anti-aging program with Austrianova. That may sound
technical, but here’s what it really means: THE COMPANY IS STEPPING
OUT OF CONCEPT MODE AND INTO REAL-WORLD PRODUCTION INFRASTRUCTURE.
By building the foundation required to scale a “longevity protein”
therapy, AVAI) is positioning itself in one of biotech’s hottest
frontiers—treating aging and chronic disease at the biological
level, not just managing symptoms.
THIS ISN’T A NICHE OPPORTUNITY. Aging, diabetes, and chronic
disease represent massive, trillion-dollar global markets—and AVAI
is developing a platform designed to plug directly into that demand
with long-term, cell-based solutions. Early-stage biotech is always
high risk, but it’s also where the biggest upside lives—and this
kind of milestone is not to be overlooked!
AVAI ISN’T JUST CHASING TRENDS—IT’S BUILDING WITHIN SOME OF THE
LARGEST MARKETS IN GLOBAL HEALTHCARE.
SEE WHY AVAI IS STARTING TO LOOK LIKE AN UNDER-THE-RADAR PLAY IN THE
EXPLOSIVE LONGEVITY AND CELL THERAPY SPACE
[[link removed]]
We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.
We would like to inform you that we have received or expect to receive
compensation in connection with the purchase or sale of the securities
of Avant Technologies (OTCQB: AVAI). The compensation consists of up
to $7,500 and was received/will be received from Interactive Offers.
This communication should not be considered as an endorsement of the
securities of adviser Avant Technologies (OTCQB: AVAI) and we are not
responsible for any errors or omissions in any information provided
about the securities of Avant Technologies (OTCQB: AVAI) by Small Caps
Daily or Interactive Offers.
We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.
This disclosure is made as of 05/15/2026.
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]
Behind the Markets
[[link removed]]
_You are receiving this email because you are subscribed to Morning
Watchlist from Behind the Markets. If you no longer wish to receive
these partner emails, please unsubscribe here
[[link removed]]._
